COMPARISON OF THE EFFICIENCY AND SAFETY OF ALBENDAZOLE AND PRAZIQUANTEL IN THE TREATMENT OF CYSTICERCOSIS
Main Article Content
Abstract
Two drugs recommended to treat cysticercosis (ATSL) are albendazole and praziquantel, however,
there have been few studies comparing these two drugs in Vietnam. Objective: To compare the
efficacy and safety of albendazole and praziquantel in the treatment of ATSL. Methods: 120 patients
with ATSL having similar clinical characteristics were grouped for treatment by albendazole or
praziquantel according to the guidelines of the Ministry of Health. The evaluation was done 6 months
after the treatment. Results: The clinically cure and improvement rates were 61.7% and 38.3%. On
MRI, the rates of complete, partial cure and inefficacy were 65%, 30.8% and 4.2% respectively.
The treatment achieved a cure rate of 51.7%, an improvement rate of 44.2% and an inefficacy rate
of 4.2%. Praziquantel was more efficacious than albendazole in clinical, MR imaging and outcome.
The studied patients did not show any abnormalities in levels of urea or creatinine. The patients
receiving praziquantel had an increase in GPT abnormalities only after the third course. The patients
taking albendazole had an increase in liver enzymes after all treatment courses. The rate of liver
enzyme elevation was higher in the albendazole group than in the praziquantel group. Conclusion:
Praziquantel is more effective and safer than albendazole in the treatment of ATSL.
Article Details
Keywords
Cysticercosis, praziquantel, albendazole, efficacy, safety.
References
BYT on issuing the Guideline on diagnosing
and treating Clonorchiasis, Paragonimus, Teania
solium and Cysticercosis, 2004.
[2] Trieu HS, Study of genes, clinical and subclinical pathogens, treating results for Teania spp
and Teania solium among patients in National
Institute of Malariology, Parasitology and
Entomology from 2007 -2010, Medical doctor’s
thesis, 2013.
[3] Hong ST, Albendazole and Praziquantel: Review
and Safety Monitoring in Korea. Infection &
chemotherapy, 2018, 50(1), 1–10
[4] Huang X, Wang Z, Kou J et al., A Large Cohort
of Neurocysticercosis in Shandong Province,
Eastern China, 1997-2015. Vector borne and
zoonotic diseases (Larchmont, N.Y.), 2019,
19(12), 901–907.
[5] Rolfs A, Mühlschlegel F, Jansen-Rosseck R et
al., Clinical and immunologic follow-up study of
patients with neurocysticercosis after treatment
with praziquantel. Neurology, 1995, 45(3 Pt
1):532-538.
[6] Pandey S, Malhotra HS, Garg RK et al.,
Quantitative assessment of lesion load and
efficacy of 3cycles of albendazole in disseminated
cysticercosis: a prospective evaluation. BMC
Infectious Diseases, 2020, 20, 220
[7] Piloiu C; Dumitrascu DL, Albendazole-Induced
Liver Injury, American Journal of Therapeutics,
2021, 28(3), p e335-e340
[8] Sotelo J, Escobedo F, Penagos P, Albendazole vs
Praziquantel for Therapy for Neurocysticercosis:
A Controlled Trial. Arch Neurol, 1988,
45(5):532–534.
[9] Sotelo J, del Brutto OH, Penagos P et al.,
Comparison of therapeutic regimen of
anticysticercal drugs for parenchymal brain
cysticercosis. J Neurol 237, 1990, 69–72.
[10] Son HJ, Kim MJ, Jung KH et al.,
Neurocysticercosis: Clinical Characteristics and
Changes from 26 Years of Experience in an
University Hospital in Korea. Korean J Parasitol,
2019, 57(3):265-271.